INFERR-Iron Infusion in Haemodialysis Study: INtravenous Iron Polymaltose for First Nations Patients With High FERRitin Levels On Haemodialysis A Protocol for a Prospective Open-Label Blinded Endpoint Randomised Controlled Trial

Sandawana William Majoni, Jane Nelson, Darren Germaine, Libby Hoppo, Stephanie Long, Shilpa Divakaran, Brandon E. Turner, Jessica Graham, Cherian Sajiv, Basant Pawar, Geetha Rathnayake, Bianca Heron, Louise Maple‐Brown, Robert A. Batey, Peter S Morris, Jane Davies, David Kiran Fernandes, Madhivanan Sundaram, Asanga Abeyaratne, Yun Hui Sheryl Wong, Paul Lawton, Sean Taylor, Federica Barzi, Alan CassResearch Square 2021 · DOI

Introduction

Anemia is a nearly universal complication of end-stage kidney disease (ESKD). Management typically involves a combination of Erythropoiesis-Stimulating Agents (ESAs) and iron supplementation. In clinical practice, treatment decisions are guided by two primary blood markers: serum ferritin, which reflects total body iron stores, and transferrin saturation (TSAT), which indicates the availability of iron for red blood cell production.

However, ferritin is a complex biomarker. While it serves as an iron storage protein, it is also an acute-phase reactant that rises significantly during periods of inflammation or infection. This dual nature creates a significant clinical dilemma, particularly for First Nations Australians in the Northern Territory, who often exhibit high ferritin levels (>700 µg/L) alongside low TSAT (<40%).

The Clinical Dilemma: The Ferritin Paradox

Current international guidelines generally advise withholding intravenous (IV) iron when ferritin levels exceed 500 or 800 µg/L to avoid the risks of iron overload, which can lead to organ damage and increased susceptibility to infections. However, in populations with high baseline inflammatory markers, these elevated ferritin levels may not indicate "too much iron." Instead, patients may experience "functional iron deficiency," where iron is sequestered and unavailable for erythropoiesis.

Withholding iron in these cases may leave anemia undertreated, necessitating higher, potentially more toxic doses of ESAs. Conversely, administering iron might risk toxicity or "feed" bacterial infections. There is currently a lack of high-quality evidence to guide the safe and effective use of iron in patients with this specific profile of hyperferritinemia and low TSAT.

The INFERR Study Design

The INFERR study (INtravenous Iron Polymaltose for First Nations Patients With High FERRitin Levels On Haemodialysis) is a prospective, open-label, blinded endpoint randomized controlled trial (PROBE design) designed to address this uncertainty.

Participants and Intervention

The study aims to recruit 576 First Nations Australians on maintenance hemodialysis from seven renal units across the Northern Territory who meet the criteria of high ferritin (700–2000 µg/L) and low TSAT (<40%). Participants are randomized 1:1 into two groups:

  • Arm A (Intervention): Patients receive 400mg of intravenous iron polymaltose once monthly (administered as 200mg during two consecutive dialysis sessions).
  • Arm B (Control/Standard Care): IV iron is withheld unless ferritin levels drop below 700 µg/L or if treatment is clinically indicated as rescue therapy.

Blinding and Data Management

While the trial is open-label—meaning patients and clinical staff are aware of the treatment assignment—the study employs a blinded endpoint design. The primary outcomes are adjudicated by an independent committee of nephrologists who remain unaware of the treatment allocation, thereby minimizing potential bias. Data is captured via the Redcap (Research Electronic Data Capture) system and tracked through hospital records and the Australian New Zealand Clinical Trials Registry (ANZCTR).

Advanced Diagnostics

To move beyond the limitations of blood biomarkers, a subset of participants will undergo MRI FerriScan. This non-invasive imaging technique is considered the "gold standard" for measuring liver iron concentration, providing a definitive assessment of whether high ferritin levels truly correlate with iron overload in this population.

Objectives and Outcomes

The INFERR trial is specifically powered to evaluate "hard" clinical endpoints rather than just surrogate laboratory markers.

  • Primary Outcome: The difference between the two study arms in the risk of a composite endpoint: all-cause death or hospitalization with a principal diagnosis of infection. The study is designed with 80% power to detect a 30% reduction in this composite outcome over a 36-month follow-up period.
  • Secondary Outcomes: These include changes in hemoglobin levels, total ESA requirements, and a comprehensive economic analysis to determine the cost-effectiveness of the intervention.

Significance and Future Impact

The results of the INFERR trial will provide much-needed evidence to resolve the uncertainty surrounding iron therapy in patients with chronic inflammation. By focusing on First Nations Australians, the study addresses a significant health equity gap, as this population is frequently excluded from large-scale global clinical trials.

Ultimately, the findings will support the development of evidence-based, culturally and clinically relevant guidelines for iron management. Furthermore, the study offers a unique opportunity to explore the underlying causes of hyperferritinemia in populations with high infectious and cardiovascular disease burdens, potentially serving as a model for managing similar cohorts worldwide.

Summary updated

Abstract

<title>Abstract</title> <bold>Background</bold>The effectiveness of erythropoiesis stimulating agents, which are the main stay of managing anaemia of chronic kidney disease (CKD) is largely dependent on adequate body iron stores. The iron stores are determined by the levels of serum ferritin concentration and transferrin saturation. These two surrogate markers of iron stores are used to guide iron replacement therapy. Most Aboriginal and/or Torres Islander Australians of the Northern Territory (herein respectively referred to as First Nation Australians) with end stage kidney disease have ferritin levels higher than current guideline recommendations for iron therapy. There is no clear evidence to guide safe and effective treatment with iron in these patients. We aim to assess the impact of intravenous iron treatment on all-cause death and hospitalisation with a principal diagnosis of all-cause infection in First Nation patients on haemodialysis with anaemia, high ferritin levels and low transferrin saturation<bold>Methods</bold>In a prospective open-label blinded endpoint randomised controlled trial, a total 576 participants on maintenance haemodialysis with high ferritin (&gt;700µg/L and ≤2000µg/L) and low transferrin saturation (&lt;40%) from 7 renal units across the Northern Territory of Australia will be randomised 1:1 to receive intravenous iron polymaltose 400mg once monthly (200mg during 2 consecutive haemodialysis sessions) (Arm A) or no IV iron treatment (standard treatment) (Arm B). Rescue therapy will be administered when the ferritin levels fall below 700µg/L or when clinically indicated. The primary outcome will be the differences between the two-study arms in the risk of hospitalisation with all-cause infection or death. An economic analysis and several secondary and tertiary outcomes analyses will also be performed.<bold>Discussion</bold>The INFERR clinical trial will address significant uncertainty on the safety and efficacy of iron therapy in First Nation Australians with CKD with hyperferritinaemia and evidence of iron deficiency. This will hopefully lead to the development of evidence-based guidelines. It will also provide the opportunity to explore the causes of hyperferritinaemia in First Nation Australians. <bold>Trial registration</bold>This trial is registered with The Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12620000705987; Registered 29 June 2020https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=378517
BibTeX
@inproceedings{majoni2021inferr,
  author = {Sandawana William Majoni and Jane Nelson and Darren Germaine and Libby Hoppo and Stephanie Long and Shilpa Divakaran and Brandon E. Turner and Jessica Graham and Cherian Sajiv and Basant Pawar and Geetha Rathnayake and Bianca Heron and Louise Maple‐Brown and Robert A. Batey and Peter S Morris and Jane Davies and David Kiran Fernandes and Madhivanan Sundaram and Asanga Abeyaratne and Yun Hui Sheryl Wong and Paul Lawton and Sean Taylor and Federica Barzi and Alan Cass},
  title = {{INFERR-Iron Infusion in Haemodialysis Study: INtravenous Iron Polymaltose for First Nations Patients With High FERRitin Levels On Haemodialysis A Protocol for a Prospective Open-Label Blinded Endpoint Randomised Controlled Trial}},
  booktitle = {Research Square},
  year = {2021},
  doi = {10.21203/rs.3.rs-877094/v1},
}
Figure